U.S. Markets closed
  • S&P Futures

    4,403.75
    -11.25 (-0.25%)
     
  • Dow Futures

    34,741.00
    -257.00 (-0.73%)
     
  • Nasdaq Futures

    15,089.50
    +43.25 (+0.29%)
     
  • Russell 2000 Futures

    2,196.90
    -22.50 (-1.01%)
     
  • Crude Oil

    68.47
    -2.09 (-2.96%)
     
  • Gold

    1,813.60
    -0.50 (-0.03%)
     
  • Silver

    25.47
    -0.11 (-0.44%)
     
  • EUR/USD

    1.1844
    -0.0024 (-0.2013%)
     
  • 10-Yr Bond

    1.2170
    +0.0330 (+2.79%)
     
  • Vix

    17.94
    -0.10 (-0.55%)
     
  • GBP/USD

    1.3900
    -0.0015 (-0.1070%)
     
  • USD/JPY

    109.4750
    +0.4250 (+0.3897%)
     
  • BTC-USD

    40,189.41
    +854.02 (+2.17%)
     
  • CMC Crypto 200

    994.82
    +18.92 (+1.94%)
     
  • FTSE 100

    7,123.86
    +18.14 (+0.26%)
     
  • Nikkei 225

    27,584.08
    -57.75 (-0.21%)
     

Neuronetics (STIM) Soars 39.2%: Is Further Upside Left in the Stock?

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Neuronetics STIM shares soared 39.2% in the last trading session to close at $14.13. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 17.1% loss over the past four weeks.

Neuronetics scored a strong price rise driven by its encouraging first-quarter 2021 results, with adjusted loss narrower than the Zacks Consensus Estimate as well as the year-ago reported figure. The quarter’s revenue too surpassed the consensus mark and exceeded the year-ago top line. The company’s raised 2021 worldwide revenue guidance also buoys optimism.

Price and Consensus

Price Consensus Chart for STIM
Price Consensus Chart for STIM

This medical device company focused on psychiatric disorders is expected to post quarterly loss of $0.33 per share in its upcoming report, which represents a year-over-year change of +51.5%. Revenues are expected to be $11.5 million, up 0.1% from the year-ago quarter.

While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.

For Neuronetics, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on STIM going forward to see if this recent jump can turn into more strength down the road.

The stock currently carries a Zacks Rank 3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Neuronetics, Inc. (STIM) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research